Plain-English translation of NCT06279104 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study that looks at medical records from patients with recurrent or persistent ovarian clear cell carcinoma to understand how well different treatments work in real-world settings. Researchers will compare the effectiveness of standard chemotherapy, immune checkpoint inhibitor-based therapy, and a combination treatment called sintilimab plus bevacizumab. The goal is to learn which approaches help patients the most.
Ovarian clear cell carcinoma is a rare and aggressive form of ovarian cancer, and when it comes back after initial treatment, options are limited. This study exists to understand which treatments work best for patients facing this difficult situation, so doctors can make better treatment decisions in the future.
You would not receive any new medication or visit a clinic for this study. Instead, researchers would review your existing medical records and health information that your doctors already have on file to see what treatments you received and how well they worked for you. The study collects this information to compare real-world outcomes across different patient groups.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China